Prognostic and predictive molecular markers: Are we ready for their clinical use? The opinion of a clinical biochemist

International Journal of Biological Markers

Volumn 18, Issue 1, 2003, Pages 62-64

  Gion, Massimo ^a  

^a GENERAL HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; CELL ADHESION MOLECULE; CYTOKERATIN; ESTROGEN; MOLECULAR MARKER; NUCLEAR PROTEIN; PROTEIN P53; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VASCULOTROPIN;

ANALYTIC METHOD; APOPTOSIS; BIOCHEMISTRY; BREAST CANCER; CANCER; CANCER SURGERY; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; CONFERENCE PAPER; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; HORMONE RESPONSE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LABORATORY TEST; METASTASIS; MOLECULAR MECHANICS; ONCOGENE; ONCOGENE NEU; PATIENT MONITORING; PREDICTION; PROGNOSIS; QUALITY CONTROL; RELIABILITY; RNA TRANSCRIPTION; STANDARDIZATION;

EID: 0142217963     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.4216     Document Type: Conference Paper

References (25)

1. Caldas C. Molecular assessment of cancer. Br Med J 1998; 316: 1360-3.
2. Gelmon KA, Eisenhauer EA, Harris AL, et al. Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development? J Natl Cancer Inst 1999; 91: 1281-7.
3. Bartelink H, Begg AC, Martin JC, et al. Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am 2000; 6: 2-10.
4. Gion M, Gasparini G: Biomarkers as therapeutic targets: Toward personalized treatments in oncology. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, eds. Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications. Washington, DC: AACC Press, 2002; 151-62.
5. Gion M: Serum tumour markers: From quality control to total quality management. Breast 2000; 9: 306-11.
6. Pfeffer U, Fecarotta E, Vidali G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res 1995; 55: 2158-65.
7. Mosselman S, Polman J, Dijkema R. ERβ: Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49-53.
8. Horowitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996; 10: 1167-77.
9. Zwijsen RM, Buckle RS, Hijmans EM, et al. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 1998; 12: 3488-98.
10. Levenson AS, Jordan VC. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium. Eur J Cancer 1999; 35: 1628-39.
11. Dowsett M, Cooke T, Ellis I, et al. Assessment of HER2 status in breast cancer: Why, when and how? Eur J Cancer 2000; 36: 170-6.
12. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771-7.
13. Dittadi R, Meo S, Amoroso B, Gion M. Detection of different estrogen receptor forms in breast cancer cytosol by enzyme immunoassay. Cancer Res 1997; 57: 1066-72.
14. Dittadi R, Meo S, Fabris F, et al. Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers 2001; 2: 87-96.
15. Tung-Ping Poon R, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-25.
16. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-35.
17. Biganzoli E, Boracchi P, Daidone MG, et al. Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers. Int J Biol Markers 1998; 13: 107-23.
18. Gion M, Gasparini G: Biological and biochemical factors in the prognosis of breast cancer. In: Dixon JM, ed. Breast Cancer: Diagnosis and Management. 2000; 289-98.
19. National Committee for Clinical Laboratory Standards. Clinical Evaluation of Immunoassays; Proposed Guideline. NCCLS document I/LA21-P, Villanoa, PA 1999.
20. Moher D. CONSORT: An evolving tool to help improve the quality of reports of randomized trials. JAMA 1998; 279: 1489-91.
21. Horton R. Medical editors trial amnesty: Unreported trial registration form. Lancet 1997; 350: 756-7.
22. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66.
23. Gion M, Boracchi P, Biganzoli E, Daidone MG. A guide for reviewing submitted manuscripts and indications for the design of translational research studies on biomarkers. Int J Biol Markers 1999; 13: 123-33.
24. Gasparini G, Gion M. Molecular-targeted anticancer therapy: Challenges related to study design and choice of proper endpoints. Cancer J Sci Am 2000; 6: 117-31.
25. Pepe SM, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054-61.